Drug Type Small molecule drug |
Synonyms Ondansetron/olanzapine |
Action antagonists |
Mechanism 5-HT2 receptor antagonists(Serotonin 2 (5-HT2) receptor antagonists), 5-HT3 receptor antagonists(5-hydroxytryptamine receptors, ionotropic (HTR3) antagonists), D1 receptor antagonists(Dopamine D1 receptor antagonists) + [1] |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H20N4S |
InChIKeyKVWDHTXUZHCGIO-UHFFFAOYSA-N |
CAS Registry132539-06-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alcoholism | Phase 1 | - | - | |
Alcoholism | Phase 1 | United States | - | - |